Dolby Laboratories Files 8-K

TL;DR

Dolby filed a routine 8-K, nothing major to see here.

AI Summary

Dolby Laboratories, Inc. filed an 8-K on June 6, 2024, to report information under Regulation FD and to file financial statements and exhibits. The filing does not contain specific financial details or material events beyond its procedural nature.

Why It Matters

This 8-K filing by Dolby Laboratories, Inc. serves as a standard disclosure to the SEC, indicating the submission of required financial statements and exhibits.

Risk Assessment

Risk Level: low — The filing is a standard procedural disclosure and does not contain new material information that would impact risk.

Key Players & Entities

• Dolby Laboratories, Inc. (company) — Registrant
• June 6, 2024 (date) — Date of earliest event reported
• 1275 Market Street San Francisco , CA 94103-1410 (address) — Principal executive offices

FAQ

Key Financial Figures

• $0.001 — which registered Class A common stock, $0.001 par value DLB The New York Stock Ex
• $429,000,000 — for an aggregate cash purchase price of $429,000,000, subject to certain purchase price adju

Filing Documents

• d699872d8k.htm (8-K) — 29KB
• d699872dex991.htm (EX-99.1) — 10KB
• 0001193125-24-155603.txt ( ) — 162KB
• dlb-20240606.xsd (EX-101.SCH) — 3KB
• dlb-20240606_lab.xml (EX-101.LAB) — 17KB
• dlb-20240606_pre.xml (EX-101.PRE) — 11KB
• d699872d8k_htm.xml (XML) — 3KB

Forward-Looking Statements

Forward-Looking Statements This Form 8-K may contain forward-looking information related to the Company and the proposed acquisition of GE Licensing by the Company, that involves substantial risks, uncertainties, and assumptions that could cause actual results to differ materially from those expressed or implied by such statements. When used in this communication, words such as "enables", "intends", "will", "expects", and similar expressions and any other statements that are not historical facts are intended to identify forward-looking statements. Forward-looking statements contained herein may include, among other things, statements about the potential benefits and financial implications of the proposed transaction, the potential impact of the proposed transaction on the Company's practices regarding quarterly dividends and share repurchases, the Company's plans, objectives, expectations, and intentions regarding GE Licensing and the assets that comprise GE Licensing, and the anticipated timing of closing of the proposed transaction. Risks and uncertainties include, among other things, risks related to the ability of the Company to consummate the proposed transaction on a timely basis or at all; the Company's ability to secure regulatory approvals on the terms expected, in a timely manner or at all; the Company's ability to successfully integrate GE Licensing's operations; the Company's ability to implement its plans, forecasts, and other expectations with respect to GE Licensing and the assets that comprise GE Licensing after the completion of the transaction and realize expected synergies; the ability to realize the anticipated benefits of the proposed transaction, including the possibility that the expected benefits from the proposed transaction will not be realized or will not be realized within the expected time period; disruption from the transaction making it more difficult to maintain business and operational relationships; risks related to diverting mana

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DOLBY LABORATORIES, INC. By: /s/ A NDY S HERMAN Andy Sherman Executive Vice President, General Counsel, and Corporate Secretary Date: June 6, 2024

View Full Filing

View this 8-K filing on SEC EDGAR